This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (46)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Neurology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

The Manhattan HIV Brain Bank

Susan Morgello, MD; Lydia Estanislao, MD; David Simpson, MD; Anthony Geraci, MD; Alessandro DiRocco, MD; Pieter Gerits, RN; Elizabeth Ryan, PhD; Tatiana Yakoushina, MD; Shafat Khan, MD; Rashid Mahboob, MD; Mubasher Naseer, MA; David Dorfman, PhD; Victoria Sharp, MD; for the Manhattan HIV Brain Bank

Arch Neurol. 2004;61:546-551.

Objectives  To examine distal sensory polyneuropathy (DSP) in a highly active antiretroviral therapy era, human immunodeficiency virus (HIV)–infected cohort, to determine whether clinical manifestations are affected by demographic or other clinical variables.

Patients  One hundred eighty-seven patients with HIV infection enrolled in the Manhattan HIV Brain Bank underwent baseline neurologic evaluations between January 29, 1999, and June 17, 2002. Distal sensory polyneuropathy was diagnosed if patients displayed abnormalities in 2 or more of the following: ankle reflexes or vibratory or pinprick perception. Patients were classified as symptomatic if they described pain, paresthesia, or numbness. Nonneurologic information was obtained by interview, laboratory testing, and medical chart review. Psychiatric and substance use disorders were elucidated by semistructured interview. In 36 patients, morphometric analysis was performed on autopsy-derived sural nerves.

Results  Of 187 patients, 99 (53%) had DSP. Patients with neuropathy were older than those without (mean ± SD age, 45.3 ± 0.7 vs 41.2 ± 0.8 years, P <.001), and DSP was significantly more common in men (58% [83/99]) than in women (37% [16/99]) (P = .02). The presence of neuropathy was not correlated with plasma viral load, decreased CD4 cell counts, or neurotoxic antiretroviral therapy. Twenty-six of 99 patients with DSP were asymptomatic. Asymptomatic neuropathy was correlated with histories of opiate and sedative abuse and dependence. Symptomatic DSP correlated with ethanol and hallucinogen syndromes, but not neurotoxic therapy. Sural nerve morphometric findings did not distinguish between patients with substance use syndromes and those without.

Conclusions  In contrast to populations before the era of highly active antiretroviral therapy, DSP in the Manhattan HIV Brain Bank cohort is not associated with increased viral load or decreased CD4 cell counts in this cross-sectional analysis. Symptoms in DSP are associated with substance use disorders, but no difference in morphologic structure is seen in nerves of patients with HIV infection with and without substance use histories. Previously reported virologic and immunologic underpinnings of DSP may be affected by highly active antiretroviral therapy. Furthermore, symptoms of DSP in substance users may be altered by central mechanisms of increased or decreased tolerance to sensory disturbance.

From the Departments of Pathology (Drs Morgello, Yakoushina, Khan, Mahboob, and Messrs Gerits and Naseer), Neurology (Drs Estanislao, Simpson, Geraci, and DiRocco), and Psychiatry (Drs Ryan and Dorfman), The Mount Sinai Medical Center; Department of Neurology (Drs Geraci and DiRocco), The Beth Israel Medical Center; and the Department of Medicine, St Luke's–Roosevelt Hospital Center (Dr Sharp), New York, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Age and height predict neuropathy risk in patients with HIV prescribed stavudine
Cherry et al.
Neurology 2009;73:315-320.
ABSTRACT | FULL TEXT  

Motor Function and Human Immunodeficiency Virus-Associated Cognitive Impairment in a Highly Active Antiretroviral Therapy-Era Cohort
Robinson-Papp et al.
Arch Neurol 2008;65:1096-1101.
ABSTRACT | FULL TEXT  

Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy
Simpson et al.
Neurology 2008;70:2305-2313.
ABSTRACT | FULL TEXT  

Putamen Hypertrophy in Nondemented Patients With Human Immunodeficiency Virus Infection and Cognitive Compromise
Castelo et al.
Arch Neurol 2007;64:1275-1280.
ABSTRACT | FULL TEXT  

Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression
Zhu et al.
Brain 2007;130:2011-2023.
ABSTRACT | FULL TEXT  

Impaired reinnervation in HIV infection following experimental denervation
Hahn et al.
Neurology 2007;68:1251-1256.
ABSTRACT | FULL TEXT  

Neurologic Disease in Captive Lions (Panthera leo) with Low-Titer Lion Lentivirus Infection
Brennan et al.
J. Clin. Microbiol. 2006;44:4345-4352.
ABSTRACT | FULL TEXT  

HIV neuropathy natural history cohort study: Assessment measures and risk factors
Simpson et al.
Neurology 2006;66:1679-1687.
ABSTRACT | FULL TEXT  

Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort
Cherry et al.
Neurology 2006;66:867-873.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus-Associated Peripheral Neuropathies
Ferrari et al.
Mayo Clin Proc. 2006;81:213-219.
ABSTRACT | FULL TEXT  

Evaluation of a clinical screening tool for HIV-associated sensory neuropathies
Cherry et al.
Neurology 2005;65:1778-1781.
ABSTRACT | FULL TEXT  

Adverse Effects Associated With Antiretroviral Therapy and Potential Management Strategies
Rudorf and Krikorian
Journal of Pharmacy Practice 2005;18:258-277.
ABSTRACT